PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 3116316-1 1987 Anticonvulsant sodium valproate, an inhibitor of GABA transaminase, which induces GABA accumulation in the brain, has been shown to possess a potent antiarrhythmic effect. Valproic Acid 15-31 4-aminobutyrate aminotransferase Homo sapiens 49-66 3129907-2 1988 injection of 800 mg of the GABA-transaminase inhibitor sodium valproate (SV) was able to suppress serum cortisol significantly when compared to saline. Valproic Acid 55-71 4-aminobutyrate aminotransferase Homo sapiens 27-44 3102338-1 1986 The effects of naloxone infusion given together with an infusion of LRH on gonadotropin secretion, were studied in 6 normal male volunteers before and after pretreatment with the GABA-transaminase inhibitor, valproic acid. Valproic Acid 208-221 4-aminobutyrate aminotransferase Homo sapiens 179-196 3080855-8 1986 Elevation in brain GABA level occurs in parallel with the anticonvulsant activity observed following valproate administration, and high levels of valproate inhibit the GABA-metabolizing enzymes GABA-T and SSADH and cause a reduction in the rate of GABA turnover. Valproic Acid 146-155 4-aminobutyrate aminotransferase Homo sapiens 194-200 3092125-0 1986 Differential effect of gamma-vinyl GABA and valproate on GABA-transaminase from cultured neurones and astrocytes. Valproic Acid 44-53 4-aminobutyrate aminotransferase Homo sapiens 57-74 6097074-3 1984 Medical treatment with the GABA-transaminase inhibitor sodium valproate induced hypocorticism necessitating corticosteroid substitution therapy. Valproic Acid 55-71 4-aminobutyrate aminotransferase Homo sapiens 27-44 218700-1 1978 The effect of sodium n dipropylacetate (nDPA), a competitive GABA-T inhibitor with respect to GABA, has been investigated on glial and neuronal cellular GABA level. Valproic Acid 14-38 4-aminobutyrate aminotransferase Homo sapiens 61-67 7387260-6 1980 A slight inhibition of GABA-T (8 to 28%) was seen only with high concentrations of trimethadione, valproate and ethosuximide. Valproic Acid 98-107 4-aminobutyrate aminotransferase Homo sapiens 23-29 354328-4 1978 The above symptoms have been associated to a deficiency of GABA after noting the very speed recovery after administration of N-dipropylacetic acid, an inhibitor of GABA transaminase. Valproic Acid 125-146 4-aminobutyrate aminotransferase Homo sapiens 164-181 13129709-0 2003 [Changes in GAT-3 and GABA-T mRNA expression of C6 glioma cells in response to a 2-week treatment with sodium valproate and withdrawal]. Valproic Acid 103-119 4-aminobutyrate aminotransferase Homo sapiens 22-28 31275777-4 2019 Sodium valproate inhibits glutamate and gamma-aminobutyric acid (GABA) transaminase while carbamazepine acts on the sodium channel - both are an important part of the retina. Valproic Acid 0-16 4-aminobutyrate aminotransferase Homo sapiens 40-83 30227132-4 2018 Comparative molecular docking study of sodium valproate (VPA) and pitavastatin was performed to predict the binding affinity with GABAA and GABA transaminase. Valproic Acid 39-55 4-aminobutyrate aminotransferase Homo sapiens 140-157 30227132-4 2018 Comparative molecular docking study of sodium valproate (VPA) and pitavastatin was performed to predict the binding affinity with GABAA and GABA transaminase. Valproic Acid 57-60 4-aminobutyrate aminotransferase Homo sapiens 140-157 27918244-0 2016 Polymorphisms of ABAT, SCN2A and ALDH5A1 may affect valproic acid responses in the treatment of epilepsy in Chinese. Valproic Acid 52-65 4-aminobutyrate aminotransferase Homo sapiens 17-21 13129709-1 2003 OBJECTIVE: To examine the effects of sodium valproate(VPA) treatment and withdrawal on the expression of GABA transporter-3 (GAT-3) and GABA transaminase (GABA-T) mRNA in C6 glioma cells, and to explore the role of GAT-3 and GABA-T in the rebound mechanism of VPA withdrawal. Valproic Acid 37-53 4-aminobutyrate aminotransferase Homo sapiens 136-153 13129709-1 2003 OBJECTIVE: To examine the effects of sodium valproate(VPA) treatment and withdrawal on the expression of GABA transporter-3 (GAT-3) and GABA transaminase (GABA-T) mRNA in C6 glioma cells, and to explore the role of GAT-3 and GABA-T in the rebound mechanism of VPA withdrawal. Valproic Acid 37-53 4-aminobutyrate aminotransferase Homo sapiens 155-161 13129709-1 2003 OBJECTIVE: To examine the effects of sodium valproate(VPA) treatment and withdrawal on the expression of GABA transporter-3 (GAT-3) and GABA transaminase (GABA-T) mRNA in C6 glioma cells, and to explore the role of GAT-3 and GABA-T in the rebound mechanism of VPA withdrawal. Valproic Acid 54-57 4-aminobutyrate aminotransferase Homo sapiens 136-153 13129709-1 2003 OBJECTIVE: To examine the effects of sodium valproate(VPA) treatment and withdrawal on the expression of GABA transporter-3 (GAT-3) and GABA transaminase (GABA-T) mRNA in C6 glioma cells, and to explore the role of GAT-3 and GABA-T in the rebound mechanism of VPA withdrawal. Valproic Acid 54-57 4-aminobutyrate aminotransferase Homo sapiens 155-161 13129709-1 2003 OBJECTIVE: To examine the effects of sodium valproate(VPA) treatment and withdrawal on the expression of GABA transporter-3 (GAT-3) and GABA transaminase (GABA-T) mRNA in C6 glioma cells, and to explore the role of GAT-3 and GABA-T in the rebound mechanism of VPA withdrawal. Valproic Acid 54-57 4-aminobutyrate aminotransferase Homo sapiens 225-231 13129709-5 2003 GABA-T mRNA expression was up-regulated to 71.31% +/-8.39% from 34.77% +/-2.36% of the control level after VPA treatment, the withdrawal of which resulted in decreased GABA-T mRNA expression. Valproic Acid 107-110 4-aminobutyrate aminotransferase Homo sapiens 0-6 13129709-5 2003 GABA-T mRNA expression was up-regulated to 71.31% +/-8.39% from 34.77% +/-2.36% of the control level after VPA treatment, the withdrawal of which resulted in decreased GABA-T mRNA expression. Valproic Acid 107-110 4-aminobutyrate aminotransferase Homo sapiens 168-174 9413804-2 1997 Sodium valproate (SV) inhibits GABA transaminase so increasing the endogenous GABAergic tone. Valproic Acid 0-16 4-aminobutyrate aminotransferase Homo sapiens 31-48 9413804-2 1997 Sodium valproate (SV) inhibits GABA transaminase so increasing the endogenous GABAergic tone. Valproic Acid 18-20 4-aminobutyrate aminotransferase Homo sapiens 31-48 1656145-6 1991 Oral administration of sodium valproate (1600 mg/day), a GABA transaminase inhibitor, enhanced the anal canal resting pressure in 10 normal volunteers. Valproic Acid 23-39 4-aminobutyrate aminotransferase Homo sapiens 57-74 8449181-5 1993 In treated patients, those receiving valproate (VPA) in monotherapy had a GABA-T activity of 15.3 +/- 7.5 pmol/min/mg, higher than both the control group and the untreated children (P < 0.001). Valproic Acid 37-46 4-aminobutyrate aminotransferase Homo sapiens 74-80 8449181-5 1993 In treated patients, those receiving valproate (VPA) in monotherapy had a GABA-T activity of 15.3 +/- 7.5 pmol/min/mg, higher than both the control group and the untreated children (P < 0.001). Valproic Acid 48-51 4-aminobutyrate aminotransferase Homo sapiens 74-80 34463268-2 2021 VPA has been shown to elevate the level of gamma-aminobutyric acid (GABA) in the brain through competitive inhibition of GABA transaminase, thus promoting the availability of synaptic GABA and facilitating GABA-mediated responses. Valproic Acid 0-3 4-aminobutyrate aminotransferase Homo sapiens 121-138